STUDII UNIVERSITARE –1990-1996, Universitatea de Medicină şi Farmacie “Gr.T.Popa”, SpecializareaMedicina Generala, titlul obtinutMedic generalist
STUDII POSTUNIVERSITARE –1997-2002, Universitatea de Medicină şi Farmacie “Gr.T.Popa” , SpecializareaBoli Infectioase, titlul obtinutMedic specialist Boli Infectioase
Doctorat – Universitatea de Medicină şi Farmacie “Gr.T.Popa”, domeniulMedicina – Boli Infectioase,titlul tezei de doctorat “Meningita tuberculoasă la copil – consideraţii clinice,diagnostice terapeutice şi evolutive”, anul sustinerii 2014, titlul obtinut Doctor.
ALTE STUDII / STAGII DE PREGĂTIRE
2003-2004, Universitatea de Medicină şi Farmacie “Gr.T.Popa” Iaşi, cursHomeopatie
2018-2019,Universitatea de Medicină şi Farmacie “Gr.T.Popa” Iaşi,Curs de Ultrasonografie Generala
25-29 octombrie 2003,EACS,1st EACS Resistance & Pharmacology Worshop, October 2003, Warsaw, Poland
14-16 februarie 2008,Institutul de Gastroenterologie si Hepatologie Iaşi,Curs intensiv de gastroenterologie
25 februarie 2016, Universitatea de Medicină şi Farmacie “Gr.T.Popa” Iaşi, Keyrus Biopharma, Workshopul ‘’Scientific abstract and poster’’
6-8 decembrie 2013, Universitatea de Medicină şi Farmacie “Gr.T.Popa” Iaşi,Cursul postuniversitar ‘’Urgente medicale si traumatice’’
3-5 decembrie 2013,Universitatea de Medicină şi Farmacie “Gr.T.Popa”, IaşiCursul postuniversitar ‘’Resuscitare cardiopulmonara de baza si avansata’’
19-21 iunie 2014, Universitatea de Medicină şi Farmacie “Gr.T.Popa” Iaşi,Scoala Medicala de Vara cu tema ‘’Patologia infectioasa – viziune transdisciplinara in era globalizarii’’
ACTIVITATEA PROFESIONALĂ
2008- in present, Medic primar – Spital Judetean de Urgenta „Sf. Ioan cel Nou” Suceava, domeniul de activitate Boli Infectioase,
2020-prezent, Sef de lucrari Universitatea „Stefan cel Mare” Suceava, Facultatea de Medicina si Stiinte Biologice.
2002- 2008, Medic specialist – Spital Judetean de Urgenta „Sf. Ioan cel Nou” Suceava, domeniul de activitate Boli Infectioase,
1997 – 2002, Medic rezident – Spital Clinic Boli Infectioase Iasi, Spital Clinic Sf. Spiridon Iasi, Spital Clinic Sf. Maria Iasi, Spital Clinic Neuochirurgie Iasi, domeniul de activitate boli Infectioase, medicina interna, pediatrie, neurologie, microbiologie, parazitologie, virusologie, terapie intensiva
Cursuri susţinute:
Îngrijiri calificate în Boli Infecțioase
Epidemiologie
Fiziologie si Fiziopatologie,
Boli Infectioase,
Patologie Medicala,
Dietoterapia si particularitati de ingrijire in Boli Infectioase,
Nursing general II,
Nursing clinic
Seminarii şi laboratoare:
Îngrijiri calificate în Boli Infecțioase
Epidemiologie
Semiologie Medicala,
Fiziologie, Fiziopatologie,
Boli Infectioase,
Patologie Medicala,
Microbiologie,
Dietoterapia si particularitati de ingrijire in Boli Infectioase,
Nursing clinic
ACTIVITATEA ŞTIINŢIFICĂ
Lobiuc A, Dimian M, Gheorghita R,Sturdza OACand Covasa M (2021) Introduction and Characteristics of SARS-CoV-2 in North-East of Romania During the First COVID-19 Outbreak. Front. Microbiol. 12:654417. doi: 10.3389/fmicb.2021.654417
M Covasa, A Lobiuc, R Gheorghita,O Sturdza, M.Dimian- Analysis of genome characteristics and transmission of SARS-CoV-2 strains in North-East of Romania during the first COVID-19 outbreak, Microbiol. 2021, vol 12, 1879
Olga Adriana Căliman-Sturdza.Dinamica afectarii hepatice in infectia cu SARS COV2. Abordarea interdisciplinara a patologiei infectioase in an pandemic. Editura “Gr.T.Popa” Iasi 2021
Olga Adriana Caliman-Sturdza.The incidence of COVID-19 among HIV-positive patients in the epidemiological outbreak Suceava. SUPPLEMENT – Medicine in Evolution Volume XXVII, No. 1, 2021, pg.34
Olga Adriana Caliman-Sturdza,Doina Mihalache, Catalina Mihaela Luca.“Performance of interferon-gamma release assay in the diagnosis of tuberculous meningitis in children.” Romanian Review of Laboratory Medicine / Revista Română de Medicină de Laborator, vol.23, nr. 2, pg. 199 – 212, 2015, https://content.sciendo.com/view/journals/rrlm/23/2/article-p199.xml
Olga Adriana Caliman-Sturdza, Hepatocarcinoma – a frequent complication of viral hepatitis B and C viral etiology, BMC Infectious Diseases, vol. 16 (Suppl 4): 46-7. ISSN: 1471-2334. 2016, (Proc. of the 12th Edition of the Scientific Days of the National Institute of Infectious Diseases “Prof. Dr. Matei Balş” and the 12th National Infectious Diseases Conference)
Olga Adriana Caliman-Sturdza, Doina Mihalache,Catalina Mihaela Luca, Carmen Dorobat. Aspecte clinico-evolutive ale meningitei tuberculoase la copil. Medical-Surgical Journal-Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi, 2010, vol.114, nr.3: 743-747; ISSN 00487848,
Olga Adriana Caliman-Sturdza, Doina Mihalache, Catalina Mihaela Luca,Cristina Petrovici, Carmen Mihaela Dorobat. Utilitatea testului QuantiFERON TB.Gold in diagnosticul menigitei tuberculoase la copil. Medical-Surgical Journal-Revista Medico-Chirurgicala Chirurgicala a Societatii de Medici si Naturalisti din Iasi, 2010, vol.114, nr.4: 1048-1052 ISSN 00487848,
Olga Adriana Caliman-Sturdza, Corina Stanescu. The value of interferon-gamma blood tests for the diagnosis of tuberculosis in HIV patients. BMC Infectious Diseases, vol. 13 (Suppl 1):P1, 13-14, 2013, (Proc. of the 9th Edition of the Scientific Days of the National Institute of Infectious Diseases “Prof. Dr. Matei Balş” and the 12th National Infectious Diseases Conference)
Olga Adriana Caliman-Sturdza. Boala Lyme – dificultati de diagnostic si tratament Revista Bucovina Medicala 2017.
Olga Adriana Caliman-Sturdza.The role of Mediterranean diet in controlling dyslipidemia associated with HIV/AIDS. Abstract Volume of the 13th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, November 2017:34-35 (ISSN 2457-8525; ISSN-L 2457-8525
Olga Adriana Caliman-Sturdza.Urgente neurologice la pacientul cu infectie HIV/SIDA. Revista Bucovina Medicala 2019.
Neurological manifestation and neuroimaging aspects in the patients wirth HIV/AIDS infection. Abstract Volume of the 13th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, November 2019 ISSN
The value of cellular interferon-gamma assays for TB diagnosis at immunocompetent and immunocompromised patients. ERJ 2007
The role of QuantiFERON TB.Gold test in diagnosis of tuberculous meningitis. ERJ 2008
The sensitivity and specificity of QuantiFERON TB.Gold in immunocompromised and immunocompetent patients. ERJ 2008
The value of interferon-gamma assay for the diagnosis of TBmeningitis in children. ERJ 2009
The QuantiFERON-TB gold test at HIV patients. ERJ 2010
PROIECTE DE CERCETARE
Studiul clinicCP40617 – A phase III, multicenter, randomized, double-blind, active-controlled study to assess the efficacy and safety of baloxavir marboxil, in combination with a neuraminidase inhibitor versus a neuraminidase inhibitor alone in hospitalized patients with severe influenza, 2018 – present, comandat de G. Hoffmann – La Roche Ltd, Elveția și PPd Global Ltd, UK, Investigator principal în unitate: Caliman Sturdza Olga Adriana
Studiul clinic201023: „A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir), in the treatment of adults hospitalized with influenza.”2017-2018, finanțat de GlaxoSmithKilne (GSK) SRL, Romania, Investigator principal în unitate : Caliman Sturdza Olga Adriana
Studiul clinic SAPPHIRE, Protocol clinic 63623872FLZ3001, studiu multicentric de faza 3, randomizat, dublu orb, controlat prin placebo, de evaluare a eficacitatii si sigurantei pimovidir in asociere cu tratamentul standard la pacientii adolescenti, adulti si varstnici spitalizati cu infecttii cu virusul gripal de tip A, și Studiul clinic DIAMOND, Protocol clinic 63623872FLZ3001, studiu multicentric de faza 3, randomizat, dublu orb, controlat prin placebo, de evaluare a eficacitatii si sigurantei pimovidir in asociere cu tratamentul standard la pacienti nespitalizati cu infectii cu virusul gripal de tip A care au risc de a dezvolta complicatii,
2018-2019,finanțat de Janssen Research & Development, Belgia,
Investigator principal în unitate : Caliman Sturdza Olga Adriana
Investigator in studiul Acti – INSP “A randomized, double-blind, parallel group, placebo controlled Phase II study to evaluate the safety and efficacy of inhaled LASAG and Placebo, applied three times daily in adult hospitalized patients with acute serious influenza” 2013-2015, finanțat de Activero GmbH. Investigatori în unitate: Stanescu Corina și Caliman Sturdza Olga Adriana
Investigator in cadrul studiului Seqirus V130-14 – V130_14 Protocol A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus’ CellBased Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine or Placebo when Administrated in Healthy Subjects aged 6 Months through 47 Months A Phase III Efficacy Study with QIVc in Pediatric Subjects din 08.2019 – in prezent. Investigatori in unitate Caliman-Sturdza Olga Adriana si Terteliu Monica.
Investigator principal in cadrul studiului international multicentric “Diagnosis of latent infection with Mycobacterium tuberculosis by T-cell interferon-ɤ release assays in immunocompromised hosts” 2009-2010, realizat de TBNET
Investigator in cadrul studiului ‘’Multinational comparison analysis using quantitative radiological evaluation in MAC pulmonary disease(MAPCD)’’ realizat de TBNET – NTM-NET, 2015-2016
Subinvestigator in cadrul studilui LIPO – lipodistrofia la pacientii cu infectie HIV/SIDA – 2007
Incidenţa hepatocarcinomului la pacienţii diagnosticaţi cu hepatita cronică sau ciroza hepatică de etiologie virală C, trataţi cu Direct Antiviral Agents (DAA), in judeţul Suceava (2019 – prezent)
Monitorizarea pacienţilor seropozitivi HIV diagnosticaţi cu dislipidemii asociate tratamentului antiretroviral – studiu in derulare – (2019 – prezent)
Investigator principal in cadrul studiului : CT-P59 3.2 “A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection” 2020 – in prezent
Investigator principal in cadrul studiului Protocol Number: SHAPERON001 Sponsor: Shaperon Inc. Protocol Title: A randomized, double blind, placebo-controlled, phase 2 clinical trial to investigate the efficacy and safety of 2 doses of NuSepin® intravenous infusion in Covid-19 pneumonia patients, 2020 – in prezent